# A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

> **NCT02582632** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 166 (actual)

## Conditions studied

- Hepatitis C Infection
- Hepatitis C Virus

## Interventions

- **DRUG:** ombitasvir/paritaprevir/ritonavir
- **DRUG:** dasabuvir

## Key facts

- **NCT ID:** NCT02582632
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-24
- **Primary completion:** 2016-08-24
- **Final completion:** 2016-12-01
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582632, "A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02582632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*